Company intelligence / Profile preview

Vivelix Pharmaceuticals

Morrisville, North Carolina, United States

Ownership: Private
Development stage: Phase 1

Overview

Vivelix Pharmaceuticals is a privately held specialty pharmaceutical company focused on developing and licensing therapies for gastrointestinal and liver diseases. Its most notable program was the exclusive worldwide license to develop IMO‑9200, an oral antagonist targeting TLR7/8/9 for non-malignant GI disorders. The company was founded by executives with significant experience in GI drug development. No recent clinical results or pipeline updates are publicly available since the initial licensing deal announced in late 2016.

Therapeutic areas: Gastroenterology
Modalities: Small molecules (notably TLR 7/8/9 antagonists)
Industry: Biotech

Drug pipeline

1 asset

IMO-9200

Unknown

Partnerships

Idera Pharmaceuticals (exclusive worldwide license for IMO‑9200)

Beyond the preview

Go deeper on Vivelix Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vivelix Pharmaceuticals.

Explore the full profile